20S Proteasome News

News

High Rate of CR Shown With Monoclonal Antibody REGN5458 for Heavily Pretreated R/R MM

03/03/2022

Nearly half of patients had a complete response with REGN5458, a BCMA-CD3 bispecific antibody monotherapy to treat heavily pretreated R/R MM.

Nearly half of patients had a...

03/03/2022

Oncology

News

Isatuximab Plus Pomalidomide and Dexamethasone: New Standard of Care for Relapsed/Refractory MM

03/02/2022

John Otrompke

A novel combination of isatuximab plus standard of care pomalidomide and dexamethasone resulted in improved OS for patients with R/R MM, according to the phase 3 ICARIA-MM trial.

A novel combination of...

03/02/2022

Oncology

News

FDA Approves BCMA-Directed CAR-T Immunotherapy for R/R MM

03/01/2022

The FDA has approved ciltacabtagene autoleucel, a novel CAR-T immunotherapy regimen to target BCMA in patients with R/R MM.

The FDA has approved...

03/01/2022

Oncology

News

Phase 3 CANDOR Trial Confirms Triplet Regimen Improves PFS for R/R MM

02/09/2022

Final analysis results of the phase 3 CANDOR study confirm improved PFS and longer follow-up outcomes of carfilzomib, daratumumab, and dexamethasone for patients with R/R MM.

Final analysis results of the...

02/09/2022

Oncology

News

Ixazomib Combo With Pomalidomide, Dexamethasone Increases PFS in Patients With R/R MM

01/28/2022

Results from a phase 1/2 study showed adding ixazomib to pomalidomide and dexamethasone as part of a second line therapy increased PFS in patients with R/R MM and warrants future phase III investigations.

Results from a phase 1/2 study...

01/28/2022

Oncology

News

Triplet Combo Therapy Provides Limited Toxicity in Relapsed MM

12/02/2021

Phase 2 data were presented at the 2021 ASH Annual Meeting for a subgroup of relapsed patients with MM who had durable responses to ixazomib, lenalidomide, and dexamethasone.

Phase 2 data were presented at...

12/02/2021

Oncology

News

20S Proteasome and UCH-L1 Concentrations Investigated as Biomarkers in TCC

10/04/2021

SPRi-based biosensors were used to analyze 20S proteasome and UCH-L1 concentrations in bodily fluids of patients with TCC to understand the relationship between ubiquitin and proteasome and cancer progression.

SPRi-based biosensors were used...

10/04/2021

Oncology

News

FDA Approves Melphalan Flufenamide for Relapsed/Refractory MM

03/03/2021

The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).

The FDA has approved melphalan...

03/03/2021

Oncology

News

FDA Approves New CAR-T Therapy for R/R Large B-Cell Lymphoma

02/19/2021

The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.

The FDA has approved...

02/19/2021

Oncology

News

Experts Show Potential of miR-100 Against MCL Cell Proliferation

10/06/2020

Findings from a clinical study suggest that miR-100 may be an anti-MCL gene.

Findings from a clinical study...

10/06/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology